CCX 872

Drug Profile

CCX 872

Alternative Names: CCX 872 B; CCX-872

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ChemoCentryx
  • Class Small molecules
  • Mechanism of Action CCR1 receptor modulators; CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Cancer; Non-alcoholic steatohepatitis
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 02 Aug 2017 Phase I development is ongoing in Netherlands (NCT02345408)
  • 02 Aug 2017 Discontinued - Preclinical for Diabetic nephropathies in USA (PO) (ChemoCentryx pipeline, August 2017)
  • 31 Mar 2017 ChemoCentryx has patent protection for CCX 872 in USA, Europe, Australia, Canada, India, Hong-Kong, Japan, and Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top